Feasibility Studies

Medherant offers rapid feasibility studies to assess the suitability of drugs for delivery using its TEPI Patch^® technology. These studies include compatibility screening with Medherant’s proprietary S-PURE adhesive, formulation of prototype patches and testing against predetermined target release profiles.

Using its proprietary high-throughput system, Medherant can test multiple formulation variants efficiently. Prototype patches are evaluated on human skin ex vivo to identify those most likely to meet the target product profile. Within just three months, Medherant’s formulation team can generate a shortlist of candidate formulations and advance them to proof-of-concept studies.

Formulations that show promise can be progressed using Medherant’s in-house pilot plant for process development and production of non-GMP test patches. From there, successful formulations can be transferred to GMP manufacture and advanced through full non-clinical and clinical development programmes.